Emerging antifungal compounds and strategies targeting Candida species: a mini-review of advances from 2010 to 2025. (PubMed, Future Med Chem) - Oct 1, 2026 - "Promising antifungal agents are presented, including ibrexafungerp, fosmanogepix, and metallacarboranes. Post-2010 research has produced a robust antifungal pipeline with first-in-class and reformulated agents targeting Candida spp. Despite encouraging laboratory and early clinical findings, the efficacy and safety of these compounds must be confirmed in large randomized clinical trials before they can be incorporated into routine clinical practice."
Clinical • Journal • Review • Candidiasis • Infectious Disease
|
|
Bartosz Mickiewicz; Monika Janeczko
|